# Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

> **NCT03004248** · PHASE3 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 2691 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** Botulinum Toxins, Type A

## Key facts

- **NCT ID:** NCT03004248
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-09
- **Primary completion:** 2018-10-17
- **Final completion:** 2018-10-17
- **Target enrollment:** 2691 (ACTUAL)
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004248, "Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03004248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*